All Stories

  1. Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
  2. Development of immortalized rhesus macaque kidney cells supporting infection with a panel of viruses
  3. Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
  4. TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
  5. Primate Simplexviruses Differ in Tropism for Macaque Cells
  6. Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
  7. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
  8. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
  9. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
  10. Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment
  11. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
  12. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
  13. Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of −1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruse...
  14. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
  15. Mutagenic Analysis of the HIV Restriction Factor Shiftless
  16. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
  17. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
  18. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
  19. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
  20. Understanding Omicron: Transmissibility, immune evasion and antiviral intervention
  21. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
  22. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
  23. Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract
  24. Omicron: Master of immune evasion maintains robust ACE2 binding
  25. Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein
  26. Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
  27. Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination
  28. Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review
  29. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
  30. Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases
  31. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
  32. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
  33. A Recombinant System and Reporter Viruses for Papiine Alphaherpesvirus 2
  34. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
  35. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
  36. Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies
  37. Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1
  38. Erythrocytes increase endogenous sphingosine 1-phosphate levels as an adaptive response to SARS-CoV-2 infection
  39. Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease
  40. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
  41. Spike residue 403 affects binding of coronavirus spikes to human ACE2
  42. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
  43. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity
  44. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
  45. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
  46. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
  47. The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection
  48. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model
  49. Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5
  50. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
  51. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
  52. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
  53. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
  54. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
  55. How SARS-CoV-2 makes the cut
  56. Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
  57. Urinary Levels of SARS-CoV-2 Nucleocapsid Protein Associate With Risk of AKI and COVID-19 Severity: A Single-Center Observational Study
  58. Therapeutic Application of alpha-1-antitrypsin in COVID-19
  59. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles
  60. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
  61. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
  62. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection
  63. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
  64. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
  65. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
  66. Mutation D614G increases SARS-CoV-2 transmission
  67. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
  68. Dalbavancin: novel candidate for COVID-19 treatment
  69. Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling
  70. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
  71. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
  72. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties
  73. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
  74. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
  75. Corrigendum: Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein–Ligand Interactions
  76. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
  77. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells
  78. Sphingosine prevents binding of SARS–CoV-2 spike to its cellular receptor ACE2
  79. Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin–Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly
  80. LY6E impairs coronavirus fusion and confers immune control of viral disease
  81. Chloroquine does not inhibit SARS-CoV-2
  82. Probing Multivalent Lectin-Carbohydrate Binding via Multifunctional Glycan-Gold Nanoparticles: Implications for Blocking Virus Infection
  83. Probing Multivalent Lectin-Carbohydrate Binding via Multifunctional Glycan-Gold Nanoparticles: Implications for Blocking Virus Infection
  84. Furin cleavage of SARS-CoV-2 spike is required for infection of lung cells
  85. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
  86. H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice
  87. Nafamostat inhibits SARS-CoV-2
  88. SARS-CoV-2 uses ACE2 and TMPRSS2 for infection of lung cells
  89. SARS-CoV-2 uses ACE2 and TMPRSS2 for infection of lung cells
  90. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus
  91. A Fosmid-Based System for the Generation of Recombinant Cercopithecine Alphaherpesvirus 2 Encoding Reporter Genes
  92. Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques
  93. Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins
  94. Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways
  95. Spike proteins of novel MERS-coronavirus isolates from North- and West-African dromedary camels mediate robust viral entry into human target cells
  96. Evidence for influenza B virus hemagglutinin adaptation to the human host: high cleavability, acid-stability and preference for cool temperature
  97. Analysis of IFITM-IFITM Interactions by a Flow Cytometry-Based FRET Assay
  98. Kaposi sarcoma in a guereza monkey
  99. Novel Virus Related to Kaposi’s Sarcoma–Associated Herpesvirus from Colobus Monkey
  100. Evidence that Calu-3 cells are largely resistant to Ebola virus entry
  101. Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis
  102. IFITM s mediate viral evasion in acute and chronic hepatitis C virus infection
  103. Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins
  104. SPP and SKI-1 inhibitor block Ebola virus entry
  105. Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance
  106. Detection of antibodies against viruses in a macaque colony using a chip-based approach
  107. The cell Line SH-SY5Y is resistant to infection by Ebola virus and other filoviruses
  108. A safe system for production of defective interfering particles
  109. Virosomes interfere with Ebola virus control by the immune system
  110. Focal epithelial hyperplasia and papillomavirus infection in a bonobo
  111. Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies
  112. Tetherin efficiently inhibits Nipah virus but not Ebola virus spread in fruit bat cells
  113. MERS-coronavirus spike protein: Importance of protease cleavage sites for viral entry
  114. A MERS-coronavirus variant that is partially resistant against neutralizing antibodies
  115. The cellular protease TMPRSS11A can convert influenza virus into an infectious form
  116. Cell Entry of Influenza A Viruses: Sweet Talk between HA and Ca V 1.2
  117. A GXXXA motif in the Ebola virus glycoprotein is required for tetherin antagonism
  118. Attachment/Binding
  119. VSV-G antagonizes tetherin in transfected cells
  120. Inhibition of lectin-dependent enhancement of Ebola virus entry into cells
  121. Identification of sites in SARS-S required cleavage and activation by TMPRSS2
  122. TMPRSS2 of non-human primates activates influenza viruses
  123. Herpes B virus replication and viral lesions in the liver of a cynomolgus macaque which died from severe disease with rapid onset
  124. pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs
  125. Rhesus macaque IFITM3 gene polymorphisms and SIV infection
  126. A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry
  127. Detection systems for antibody responses against herpes B virus
  128. Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide
  129. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
  130. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies
  131. The Role of Phlebovirus Glycoproteins in Viral Entry, Assembly and Release
  132. The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells
  133. Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions
  134. Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions
  135. The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent
  136. The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases
  137. TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells
  138. Exclusive Decoration of Simian Immunodeficiency Virus Env with High-Mannose Type N-Glycans Is Not Compatible with Mucosal Transmission in Rhesus Macaques
  139. Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase
  140. Interferon-Induced Transmembrane Protein–Mediated Inhibition of Host Cell Entry of Ebolaviruses
  141. Analysis of Ebola Virus Entry Into Macrophages
  142. Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976
  143. Protease inhibitors targeting coronavirus and filovirus entry
  144. IFITM Proteins Inhibit Entry Driven by the MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms
  145. DESC1 and MSPL Activate Influenza A Viruses and Emerging Coronaviruses for Host Cell Entry
  146. Inhibition of Proprotein Convertases Abrogates Processing of the Middle Eastern Respiratory Syndrome Coronavirus Spike Protein in Infected Cells but Does Not Reduce Viral Infectivity
  147. Bitter-sweet symphony: glycan–lectin interactions in virus biology
  148. Influenza A Virus Encoding Secreted Gaussia Luciferase as Useful Tool to Analyze Viral Replication and Its Inhibition by Antiviral Compounds and Cellular Proteins
  149. Analysis of Determinants in Filovirus Glycoproteins Required for Tetherin Antagonism
  150. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry
  151. Induced and spontaneous heart rate turbulence in mice: influence of coupling interval
  152. Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4+ T Cells
  153. Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice
  154. Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
  155. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research
  156. TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein
  157. Platelet activation suppresses HIV-1 infection of T cells
  158. TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium
  159. The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies
  160. Severe Fever with Thrombocytopenia Virus Glycoproteins Are Targeted by Neutralizing Antibodies and Can Use DC-SIGN as a Receptor for pH-Dependent Entry into Human and Animal Cell Lines
  161. Cellular Entry of Retroviruses
  162. Attachment/Binding
  163. Host Cell Factors in Filovirus Entry: Novel Players, New Insights
  164. The role of the alternative coreceptor GPR15 in SIV tropism for human cells
  165. How Ebola Virus Counters the Interferon System
  166. Influenza A Virus Does Not Encode a Tetherin Antagonist with Vpu-Like Activity and Induces IFN-Dependent Tetherin Expression in Infected Cells
  167. Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts
  168. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression
  169. CD4- and dynamin-dependent endocytosis of HIV-1 into plasmacytoid dendritic cells
  170. Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells
  171. The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin
  172. The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors
  173. Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease
  174. DC-SIGN: Access Portal for Sweet Viral Killers
  175. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion
  176. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
  177. Mouse LSECtin as a model for a human Ebola virus receptor
  178. The multiple facets of HIV attachment to dendritic cell lectins
  179. Novel insights into proteolytic cleavage of influenza virus hemagglutinin
  180. TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells
  181. A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms
  182. Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2
  183. Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion Proteins
  184. Calcium-modulating cyclophilin ligand does not restrict retrovirus release
  185. Lectin-like interactions in virus–cell recognition
  186. Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63
  187. Cellular Entry of the SARS Coronavirus: Implications for Transmission, Pathogenicity and Antiviral Strategies
  188. Type II transmembrane serine proteases in cancer and viral infections
  189. Proteolytic Activation of the 1918 Influenza Virus Hemagglutinin
  190. Carbohydrates on HIV: mediators of immune evasion and targets for antiviral intervention
  191. Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding
  192. Analysis of the Interaction of Ebola Virus Glycoprotein with DC‐SIGN (Dendritic Cell–Specific Intercellular Adhesion Molecule 3–Grabbing Nonintegrin) and Its Homologue DC‐SIGNR
  193. A Novel Mechanism for LSECtin Binding to Ebola Virus Surface Glycoprotein through Truncated Glycans
  194. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin
  195. Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
  196. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo
  197. The C-type Lectin Receptors CLEC-2 and Dectin-1, but Not DC-SIGN, Signal via a Novel YXXL-dependent Signaling Cascade
  198. Attachment of human immunodeficiency virus to cells and its inhibition
  199. DC-SIGN and CLEC-2 Mediate Human Immunodeficiency Virus Type 1 Capture by Platelets
  200. Modulation of virion incorporation of Ebolavirus glycoprotein: Effects on attachment, cellular entry and neutralization
  201. Highly Conserved Regions within the Spike Proteins of Human Coronaviruses 229E and NL63 Determine Recognition of Their Respective Cellular Receptors
  202. The Signal Peptide of the Ebolavirus Glycoprotein Influences Interaction with the Cellular Lectins DC-SIGN and DC-SIGNR
  203. Cellular Entry of HIV: Evaluation of Therapeutic Targets
  204. Impact of polymorphisms in the DC-SIGNR neck domain on the interaction with pathogens
  205. Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN
  206. Evidence that multiple defects in murine DC-SIGN inhibit a functional interaction with pathogens
  207. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2
  208. Interaction Between the Spike Protein of Human Coronavirus NL63 and its Cellular Receptor ACE2
  209. Attachment Factor and Receptor Engagement of Sars Coronavirus and Human Coronavirus NL63
  210. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus
  211. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
  212. DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus
  213. Cellular entry of the SARS coronavirus
  214. Differential regulation of human immunodeficiency virus type 2 and simian immunodeficiency virus promoter activity
  215. Prospects of HIV‐1 entry inhibitors as novel therapeutics
  216. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor
  217. S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients
  218. Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors
  219. Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency
  220. Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
  221. Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR
  222. DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells
  223. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
  224. Diversity of receptors binding HIV on dendritic cell subsets
  225. Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells
  226. The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination?
  227. Hemofiltrate CC Chemokine 1[9-74] Causes Effective Internalization of CCR5 and Is a Potent Inhibitor of R5-Tropic Human Immunodeficiency Virus Type 1 Strains in Primary T Cells and Macrophages
  228. CD4 Independence of Simian Immunodeficiency Virus Envs Is Associated with Macrophage Tropism, Neutralization Sensitivity, and Attenuated Pathogenicity
  229. Evaluation of Current Approaches to Inhibit HIV Entry
  230. Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques
  231. DC-SIGN and DC-SIGNR: helping hands for HIV
  232. Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN
  233. DC-SIGN Interactions with Human Immunodeficiency Virus: Virus Binding and Transfer Are Dissociable Functions
  234. Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV
  235. The Role of DC-SIGN and DC-SIGNR in HIV and SIV Attachment, Infection, and Transmission
  236. Basic Amino Acid Residues in the V3 Loop of Simian Immunodeficiency Virus Envelope Alter Viral Coreceptor Tropism and Infectivity but Do Not Allow Efficient Utilization of CXCR4 as Entry Cofactor
  237. DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus
  238. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans
  239. Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties
  240. Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry
  241. Co‐receptor Usage of BOB/GPR15 in Addition to CCR5 Has No Significant Effect on Replication of Simian Immunodeficiency Virus In Vivo